Kate A. Shanaghan - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Kate A. Shanaghan's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Kate A. Shanaghan
Verified
Writer, Haymarket Media
Ventura
Beats
Veterinary Medicine
Content
By Sophie Gao, Kate A. Shanaghan Verified| Rheumatology Advisor Verified Throughout 2024, the United States Food and Drug Administration (FDA) approved new drugs for the treatment of osteoporosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), giant cell arteritis, Duchenne muscular dystrophy (DMD), and certain cancers, while also expanding treatment indications for previously approved drugs. On March 5, 2024, the FDA approved Jubbonti, the first interchangeable biosimilar for Prolia® (denosumab).
By Kate A. Shanaghan Verified| Rheumatology Advisor Verified The process of being diagnosed with an autoimmune disease is rarely linear. This proved especially true for Talisa King, who was diagnosed with rheumatoid arthritis (RA) when she was only 31 years of age. King, who was officially diagnosed with RA back in 2012, is an African American woman living in Buffalo, New York. Prior to her diagnosis, she was not symptomatic.
By Sophie Gao, Kate A. Shanaghan Verified| Rheumatology Advisor Verified Throughout 2024, the United States Food and Drug Administration (FDA) approved new drugs for the treatment of osteoporosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), giant cell arteritis, Duchenne muscular dystrophy (DMD), and certain cancers, while also expanding treatment indications for previously approved drugs. On March 5, 2024, the FDA approved Jubbonti, the first interchangeable biosimilar for Prolia® (denosumab).
Company Info
Haymarket Media
McMahons Point, New South Wales, Australia
'+61 2 8399 7636